

ECONOMIC IMPACT OF THE INTRODUCTION OF A Sacyl **COMPOUNDED 50 MG/ML MERCAPTOPURINE SUSPENSION IN A TEACHING HOSPITAL**

M.E. Cárdaba García¹, M. Izquierdo Navarro¹, A. Salvador Palacios¹, S. Fernández Peña¹, S. Izquierdo Muñoz¹. ¹Hospital Clínico Universitario, Hospital Pharmacy, Valladolid, Spain.

Background

Mercaptopurine is indicated for the treatment of acute lymphoblastic leukemia (ALL). In our country there is no commercial presentation that allows proper dosage in pediatric patients. However, in March-2012, an expensive 20 mg/mL mercaptopurine suspension that may be purchased as a foreign drug was commercialized. In order to meet the needs of these patients using a more cost-effective alternative, the Pharmacy Department developed a mercaptopurine compounded drug.

Objective

To assess the economic impact brought by the development of a 50 mg/mL mercaptopurine suspension (12 mL) compared with the use of commercial syrup.

Material and methods

<u>50 mg/mL mercaptopurine suspension</u>

Simple syrup + cherry syrup + sterile water + mercaptopurine 50 mg triturated tablets

- Retrospective study (March 2012 September 2015)
- Collected data, from Farmatools[®] and Farmis [®] softwares: number of ALL patients treated with the suspension, suspensions dispensed, mercaptopurine tablets used and its cost, treatment phase of the ALL-SEHOP-PETHEMA protocol when the dispensation was done.
- <u>Suspension appraisal</u>: valuation rules of the Regional Health Management
- Commercial suspension price: Ministry of Health Web Site.
- Total saving: direct cost of commercial suspension direct cost of compounded suspension

Results



- 40 compounded mercaptopurine suspensions (50 mg/mL): 2 for consolidation phase and 38 for maintenance phase
- Shelf-life: 28 days

Conclusion

- 20 commercial mercaptopurine suspensions would have been needed
- Shelf-life: 56 days
- 269.36 €/each one
- Total expenditure: 5,387.2 €

28.1 €/each one

Total expenditure: 1,124 €



 Compounded 50 mg/mL mercaptopurine suspension can meet therapeutic needs of ALL pediatric patients and save costs.

• It would be useful to assess the addition of a preservative to the

compounded suspension to increase its shelf-life and save on costs.

No conflict of interest



Xalupr